Reuters logo
BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine
October 23, 2017 / 9:03 PM / 2 months ago

BRIEF-Neurocrine granted FDA orphan drug designation for Valbenazine

Oct 23 (Reuters) - Neurocrine Biosciences Inc

* Neurocrine granted FDA orphan drug designation for valbenazine for the treatment of pediatric patients with Tourette syndrome Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below